Back to top
more

Genmab (GMAB)

(Delayed Data from NSDQ)

$28.15 USD

28.15
339,610

+0.69 (2.51%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $28.14 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GMAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Genmab A/S Sponsored ADR [GMAB]

Reports for Purchase

Showing records 61 - 80 ( 109 total )

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 61

01/15/2021

Company Report

Pages: 4

DARZALEX Faspro Front Line Approval; Reiterate Buy; Raising PT to $49

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 62

01/05/2021

Company Report

Pages: 5

Tisotumab Vedotin Pivotal Trial Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 63

12/23/2020

Company Report

Pages: 4

Canadian Approval of CASSIOPEIA Regimen; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 64

12/14/2020

Company Report

Pages: 7

Numerous Key Takeaways From ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 65

12/04/2020

Company Report

Pages: 5

Amivantamab Submitted for Approval in Lung Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 66

11/25/2020

Company Report

Pages: 5

Enapotamab Vedotin Axed; Teclistamab Orphan Designation; Reducing PT to $44

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 67

11/19/2020

Company Report

Pages: 5

New DARZALEX Submission; GEN1046 SITC Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 68

11/06/2020

Company Report

Pages: 5

Epcoritamab Phase 3 Trial in 2L+ DLBCL Poised to Start; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 69

11/05/2020

Company Report

Pages: 7

3Q20 Financial Results; Epcoritamab ASH Abstract Impresses; Raising PT to $45

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 70

10/22/2020

Company Report

Pages: 5

Part 2 of CASSIOPEIA Achieves Statistical Significance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 71

09/23/2020

Company Report

Pages: 5

ESMO 2020 Tisotumab and Amivantamab Data; Reiterate Buy: Raising PT to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 72

08/21/2020

Company Report

Pages: 5

Kesimpta and DARZALEX Approvals; Raising PT to $41

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 73

08/13/2020

Company Report

Pages: 5

Genmab Refines Guidance; 2Q20 Financials Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 74

08/03/2020

Company Report

Pages: 4

DARZALEX Faspro Phase 3 APOLLO Trial Meets Primary Endpoint; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 75

07/17/2020

Company Report

Pages: 4

DARZALEX 2Q20 Sales Roughly in Line With Forecast; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 76

06/30/2020

Company Report

Pages: 4

Tisotumab Phase 2 Results Appear In Line With Prior Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 77

06/15/2020

Company Report

Pages: 4

ANDROMEDA Establishes New Key AL Amyloidosis Regimen; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 78

06/12/2020

Company Report

Pages: 9

Initial Takeaways From EHA 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 79

06/11/2020

Company Report

Pages: 6

AbbVie Partnership Cements Genmab''s Long-Term Strategy; Raising PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Genmab A/S Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 80

06/05/2020

Company Report

Pages: 5

Subcutaneous Daratumumab Form Wins European Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party